Novo launches Ozempic and Fiasp in U.S.

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) launched in the U.S. Ozempic semaglutide (NN9535) to treat Type II diabetes in adults and Fiasp rapid-acting insulin (NN1218) analog to improve glycemic control in adults with Type I and Type II diabetes.

In December, FDA approved Ozempic, the once weekly, long-acting glucagon-like peptide-1 (GLP-1) analog, as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes. Ozempic's wholesale acquisition cost (WAC) is $676 for two pens plus four needles for the 1 mg dose and $676 for one pen and six needles of the 0.25 or 0.5 mg doses. The concentration is 2 mg per 1.5 ml. The recommended starting dose is once-weekly 0.25 mg for four weeks followed by once-weekly 0.5 or 1 mg doses...